logo
Share SHARE
FONT-SIZE Plus   Neg

UCB'Kremers Gets FDA Approval For Extended Release Methylphenidate Hydrochloride

UCB announced Wednesday that its U.S. subsidiary, Kremers Urban Pharmaceuticals Inc. or KU, received approval from the U.S. Food and Drug Administration or FDA for 18mg and 27mg extended release methylphenidate hydrochloride product, for which Concerta is the reference listed drug product.

KU has begun launch operations and supplying the US-market with the product. KU also received tentative approval for the 36mg and 54mg. KU will be eligible for final approval after exclusivity expiration in September 2013.

KU's extended release methylphenidate hydrochloride product is bioequivalent to Concerta QD marketed by ALZA Corporation, a unit of Johnson & Johnson (JNJ). Each tablet is designed to be effective for 12-hours.

In September 2011, KU announced that it has reached a settlement dismissing all pending litigation arising from its Abbreviated New Drug Application or ANDA to market an extended release methylphenidate hydrochloride product. The settlement allows Kremers Urban to commercially launch its methylphenidate ANDA product under the existing ALZA Corporation patents.

UCB noted that the launch of KU's new generic product was already considered in its 2013 financial guidance.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Rare commodities are worth more than good is a Chinese adage. And more so when it is in the sought-after drug space. Rare and ultra-rare diseases, also called orphan and ultra-orphan diseases, as the names imply, affect very small numbers of patients. So why the clamor? Shares of steel giant ArcelorMittal were losing around 4 percent in the early morning trading in Amsterdam after the company reported sharp decline in first-quarter EBITDA, a key earnings metric, as sales were weak with lower prices and production. Net loss, however, narrowed from last year. The company also confirmed its forecast for annual EBITDA, which is lower than last year. As the din settles down on a dismal quarter at one of the world's exciting tech company, it is time to sit back and take stock of what went wrong and will the wrong be righted in the near term?
comments powered by Disqus
Follow RTT